Published in

American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 1(57), p. 668-671, 2013

DOI: 10.1128/aac.00985-12

Links

Tools

Export citation

Search in Google Scholar

Colistin Methanesulfonate and Colistin Pharmacokinetics in Critically Ill Patients Receiving Continuous Venovenous Hemodiafiltration

Journal article published in 2012 by Matti Karvanen, Diamantis Plachouras, Lena E. Friberg, Elisabeth Paramythiotou, Evangelos Papadomichelakis, Ilias Karaiskos, Iraklis Tsangaris, Apostolos Armaganidis, Otto Cars, Helen Giamarellou ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

ABSTRACT This report describes the pharmacokinetics of colistin methanesulfonate (CMS) and colistin in five intensive care unit patients receiving continuous venovenous hemodiafiltration. For CMS, the mean maximum concentration of drug in plasma ( C max ) after the fourth dose was 6.92 mg/liter and total clearance (CL) 8.23 liters/h. For colistin, the mean concentration was 0.92 mg/liter and CL/metabolized fraction (f m ) 18.91 liters/h. Colistin concentrations were below the current MIC breakpoints, and the area under the concentration-time curve for the free, unbound fraction of the drug over 24 h in the steady state divided by the MIC ( f AUC/MIC) was lower than recommended, suggesting that a dosage regimen of 160 mg CMS every 8 h (q8h) is inadequate.